The latest GPUs need a type of rare earth metal called Dysprosium and there are only 28 companies in the world exploring or producing it. Find the list for free.
To own Azenta, I think you need to believe its sample management and multiomics services can convert steady life sciences demand into durable profitability, despite recent years of losses and industry budget pressures. The return to quarterly profitability and higher full-year revenue guidance support that case in the near term, but the biggest risk remains that ongoing softness in certain sequencing and synthesis lines, combined with elevated R&D and infrastructure spend, could still hold back margins and free cash flow. Overall, this quarter’s news looks helpful but not transformational to that risk-reward balance.
Among the recent company updates, the completion of the US$50 million repurchase of 2,300,000 shares stands out alongside the earnings release, as it meaningfully reduced the share count while Azenta reported positive quarterly net income of US$2.46 million on revenue of US$161.18 million. For investors focused on short term catalysts, this pairing of buybacks with a return to profitability may sharpen attention on how consistently Azenta can sustain positive earnings from here.
Yet even with these improvements, investors should be aware that ongoing pressure on high margin instruments and services could still...
Read the full narrative on Azenta (it's free!)
Azenta's narrative projects $685.0 million revenue and $37.8 million earnings by 2029. This requires 4.7% yearly revenue growth and a $148.7 million earnings increase from -$110.9 million today.
Uncover how Azenta's forecasts yield a $27.80 fair value, a 17% downside to its current price.
Some of the lowest analysts were assuming Azenta would reach only about US$678.7 million in revenue and US$33.5 million in earnings by 2029, so this quarter’s profitability and guidance raise could challenge that more pessimistic view of margin pressure and slow improvement, and it is worth weighing how your own expectations compare before deciding which narrative you find more convincing.
Explore 2 other fair value estimates on Azenta - why the stock might be worth as much as $27.80!
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com